RPRXMEDIUM SIGNALFINANCIAL10-K

Royalty Pharma expanded its royalty portfolio with new products while experiencing a substantial increase in credit loss provisions and mixed financial performance.

The company added several new commercial products to its royalty portfolio including Vertex's Alyftrek, Servier's Voranigo, Amgen's Imdelltra, and Alnylam's Amvuttra, indicating successful business development activity. However, the doubling of credit loss provisions suggests increased concern about collectibility of certain royalty receivables, which could signal challenges with specific portfolio assets or a more conservative accounting approach.

Comparing 2026-02-11 vs 2025-02-12View on EDGAR →
FINANCIAL ANALYSIS

RPRX delivered solid operating income growth of 20.7% despite substantially higher credit loss provisions that nearly doubled year-over-year. The company's balance sheet shows increased leverage with total debt rising 17.6% and total liabilities expanding 25.7%, while cash declined 33.4% and current liabilities dropped significantly by 49.2%. Operating cash flow declined modestly by 10.1%, reflecting the mixed operational performance as the company continues investing in portfolio expansion while managing credit quality concerns.

FINANCIAL STATEMENT CHANGES
Provision for Credit Losses
P&L
+96.2%
$230.8M→$452.8M

Credit loss provisions surged 96.2% — management flagging significant deterioration in loan quality ahead.

Current Liabilities
Balance Sheet
-49.2%
$1.3B→$636.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Cash & Equivalents
Balance Sheet
-33.4%
$929.0M→$618.7M

Cash declined 33.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
+25.7%
$7.9B→$9.9B

Liabilities increased 25.7% — monitor debt-to-equity ratio and interest coverage.

Operating Income
P&L
+20.7%
$1.3B→$1.6B

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Debt
Balance Sheet
+17.6%
$7.6B→$9.0B

Debt rose 17.6% — additional borrowing for investment or operations; monitor coverage ratios.

Current Assets
Balance Sheet
-15.2%
$1.8B→$1.5B

Current assets declined 15.2% — monitor working capital adequacy and short-term liquidity.

Net Income
P&L
-10.2%
$859.0M→$770.9M

Net income declined 10.2% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-10.1%
$2.8B→$2.5B

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-02-11
PRIOR — 2025-02-12
ADDED
As of February 6, 2026, Royalty Pharma plc had 428,418,612 Class A ordinary shares outstanding and 148,438,141 Class B ordinary shares outstanding.
We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry s leading therapies, which includes royalties on more than 35 commercial products, including Vertex s Trikafta and Alyftrek, GSK s Trelegy, Biogen s Tysabri and Spinraza, Roche s Evrysdi, Astellas and Pfizer s Xtandi, Johnson Johnson s Tremfya, AbbVie and Johnson Johnson s Imbruvica, Servier s Voranigo, Gilead s Trodelvy, Amgen s Imdelltra and Alnylam s Amvuttra, among others, and 20 development-stage product candidates.
We strive to be the premier capital allocator in life sciences with consistent, compounding growth.
Our highly selective investment approach focuses on identifying and tracking important new therapies, which allows us to act efficiently when opportunities arise.
Supported by an experienced investment team, a rigorous due diligence process and a focus on high-quality therapies addressing significant unmet patient needs, we pursue royalty opportunities that best meet our investment criteria.
+7 more — sign up free →
REMOVED
As of February 7, 2025, Royalty Pharma plc had 433,324,905 Class A ordinary shares outstanding and 143,128,262 Class B ordinary shares outstanding.
We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry s leading therapies, which includes royalties on more than 35 commercial products, including Vertex s Trikafta, GSK s Trelegy, Roche s Evrysdi, Johnson Johnson s Tremfya, Biogen s Tysabri and Spinraza, AbbVie and Johnson Johnson s Imbruvica, Astellas and Pfizer s Xtandi, Novartis Promacta, Pfizer s Nurtec ODT, Gilead s Trodelvy, among others, and 14 development-stage product candidates.
We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators.
Our industry leading royalty portfolio and capital-efficient business model drives our compounding growth.
We have a focused strategy of actively identifying and tracking the development and commercialization of important new therapies, which allows us to move quickly to make acquisitions when opportunities arise.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →